Rituximab: Ongoing and future clinical development.

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Monoclonal antibodies are established therapeutic agents.
• Rituximab (Rituxan/MabThera) was the first monoclonal antibody approved by the US FDA for a cancer indication in 1997.
• It is indicated for CD20-positive B-cell non-Hodgkin's lymphoma.

Purpose of the Study:

• To review the clinical applications of rituximab.
• To discuss ongoing and future clinical trials.
• To identify areas for further research in monoclonal antibody therapy.

Main Methods:

• Review of clinical research and trial data.
• Analysis of regulatory approvals and physician communications.
• Synthesis of information on therapeutic applications.

Main Results:

• Rituximab approval in the US (1997) and EU (1998) for non-Hodgkin's lymphoma.
• Over 125,000 patients treated in the US alone.
• Significant interest generated in therapeutic monoclonal antibodies, with dozens under investigation.

Conclusions:

• Rituximab has demonstrated significant clinical utility and heightened interest in monoclonal antibody therapeutics.
• Further research is needed for optimizing combinations with chemotherapy, biologics, and radiotherapy.
• Exploration of rituximab in other malignant and non-neoplastic conditions is warranted.